ACS Medicinal Chemistry Letters Innovations Webinar

ACS Medicinal Chemistry Letters

Innovations Webinar:

Fueling the Pipeline via Innovations in Organic Synthesis

Held on Monday, November 8, 2021

NOW AVAILABLE TO WATCH ON-DEMAND

ACS Medicinal Chemistry Letters Innovations Webinar:

Fueling the Pipeline via Innovations in Organic Synthesis

Speaker:

Eric A. Voight, Ph.D.

AbbVie

Moderator:

Dani Schultz, Ph.D.

Merck

Summary:

Efficient and innovative Organic Synthesis can reduce cycle time and cost of goods for Pharmaceutical R and D operations. Of late, significant efforts within the Industry have been expended to utilize specialized synthesis teams in the Discovery space. These teams provide, amongst other things, specialist synthetic expertise, including the ability to rapidly solve difficult synthesis challenges and identify new and efficient routes to key target molecules. This impacts the early-stage production of larger quantities of key target molecules and provides workable synthetic routes to development candidates that can be effectively handed off to Process Chemistry groups. Two such groups are in place at AbbVie and Merck. Eric Voight (AbbVie) will give our 2nd ACS Medicinal Chemistry Letters Innovations Webinar entitled "Fueling the Pipeline via Innovations in Organic Synthesis" and will be introduced by Dani Schultz from the Merck group. The overarching theme of the talk and discussions will be centered around the demonstration of the high value of such Synthesis groups in the Discovery space.

Registration Form

Email Address*

First Name*

Last Name*

Country*

Institution or Company

Title/Job Role

I would like to receive more information on products and services from the American Chemical Society

Speakers:

Eric A. Voight

Dr. Eric A. Voight

AbbVie

Eric A. Voight obtained his Ph.D. in organic chemistry from the University of Wisconsin-Madison (UWM) in 2004 in Steve Burke’s laboratory. Since then, he has established his career in the pharmaceutical industry, first as a process chemist at Merck and GSK, then joining AbbVie in 2008, where he is currently a Research Fellow. He is the Founder and Leader of the Centralized Organic Synthesis (COS) group within Centralized Medicinal Chemistry (CMeC), a discovery synthesis group that started in 2012. Furthermore, his work at AbbVie has contributed to the discovery, synthesis, or co-invention of 33 AbbVie clinical candidates across Neurology, Oncology, Cystic Fibrosis, Immunology, and Immuno-oncology, including Foslevodopa/Foscarbidopa, which is in Phase III clinical trials for Parkinson’s Disease, as well as galicaftor, currently in Phase II clinical trials for Cystic Fibrosis. He has coauthored 37 publications, is a coinventor on 23 patents, and has been invited to give more than 15 chemistry lectures. When he’s not working, Eric enjoys spending time with his family, including his six kids between the ages of 1 and 19.

Dani Schultz

Dr. Dani Schultz

Merck

Dani Schultz received her Ph.D. from the University of Michigan working with Professor John Wolfe and was an NIH postdoctoral fellow at the University of Wisconsin-Madison with Professor Tehshik Yoon. Since joining Merck in 2014, Dani has been a member of Process Chemistry and Enabling Technologies in Rahway, NJ and as of 2021 became the Director of the Discovery Process Chemistry group in Kenilworth, NJ. Throughout her time at Merck, Dani has been involved in the development of synthetic routes for drug candidates spanning HIV and oncology – forging meaningful collaborations, both internally and externally, to address the synthetic challenges that occur during pharmaceutical development.

Agenda

What You Will Learn:

The overarching theme of the talk and discussions will be centered around the demonstration of the high value of such Synthesis groups in the Discovery space.